Arno Therapeutics
This article was originally published in Start Up
Executive Summary
In addition to camptothecins and HDAC inhibitors, Arno Therapeutics Inc.'s pipeline of cancer candidates includes a Phase I agent that targets the PI3K/Akt pathway. Arno thinks it's potentially a first-in-class compound that could have broad activity against a range of solid and liquid tumors. Furthermore, preclinical data show synergy with approved targeted agents.